Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Incidence: lung cancer · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in incidence: lung cancer compared with placebo (low certainty).
1 finding from 1 review
Mortality: lung cancer · relatively healthy postmenopausal women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: renal calculi · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in adverse events: renal calculi compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: serum calcium above normal · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in adverse events: serum calcium above normal compared with placebo (low certainty).
1 finding from 1 review
Incidence: all cancers · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in incidence: all cancers compared with placebo (low certainty).
1 finding from 1 review
Mortality: all cancers · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in mortality: all cancers compared with placebo (moderate certainty).
1 finding from 1 review
Mortality: all causes · relatively healthy postmenopausal women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'response' by PGA compared with steroid (high certainty).
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'clearance' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid plus vitamin D showed no clear difference in number of participants withdrawing due to adverse events (AE) compared with steroid (moderate certainty).
1 finding from 1 review
PTH · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Number without 30% fall in PTH on two occasions · patients with bone disease in children with chronic kidney disease
Vitamin D preparations may leads to lower number without 30% fall in PTH on two occasions compared with placebo/no treatment (low certainty).
1 finding from 1 review
Hypercalcaemia · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Change in calcium‐phosphorus product mg(2)/dL(2) · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review